Isolation and use of solid tumor stem cells

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The The Regents Of The University Of Michigan patent solves the following problem:

Cancer remains the number two cause of death in this country, resulting in more than 500,000 deaths each year. Despite progress in detection and treatment, cancer mortality remains high. Despite remarkable progress in understanding the molecular basis of cancer, this knowledge has not yet translated into effective therapeutic strategies. In particular, breast cancer is the most common cancer among American women, with an estimated one in nine women will develop breast cancer in their lifetime. Unfortunately, metastatic breast cancer is still an incurable disease. Most women with metastatic breast cancer succumb to the disease.

Our analysis of this patent is as follows:

The Regents Of The University Of Michigan’s patent US 7713710 B2 deals with Isolation and use of solid tumor stem cells.
A small percentage of cells in a solid tumor on the properties of stem cells. These strong tumor stem cells give rise to two more tumor stem cells and the majority of tumor cells that have lost the capacity for growth and the ability to give rise to new tumors. The strong tumor heterogeneity appeared before the tumor cell line arising from a strong tumor stem cells. discovery This is the basis for strong tumor stem cell compositions, methods for their functionally different populations of tumor cells, methods of using these tumor cell populations for the study of the therapeutic effects agents in tumor growth, and ways to identify and test novel anti-cancer treatments are aimed to strengthen the tumor stem cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

BTL-II nucleic acids

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Immunex Corporation patent solves the following problem:

Modulation of an immune or inflammatory response can be a valuable tool to control various types of diseases including autoimmune diseases, diseases characterized by abnormal inflammation and / or immune response, and infections . In treating diseases characterized by abnormal inflammation and / or immune responses, such as inflammatory bowel disease and autoimmune or inflammatory diseases, modulation of an immune response is desirable. In other situations, for example when the vaccine to a patient to give immunity to an infectious disease, stimulation of an immune response is desirable. In the case of vaccines, adjuvants on an immune response to a coadministered antigen can be valuable in providing long term protection against the disease. Particularly lacking in the art is the adjuvants capable of stimulating a mucosal immune response. A mucosal immune response, as opposed to a systemic immune response, is valuable because it attacks an infection with a very common point of entry, that is, to a mucosal surface. The present invention addresses these needs in the art by providing therapeutic agents for the diagnosis and treatment of diseases characterized by inadequate and / or abnormal inflammation and / or immune response and therapeutic agents that act as adjuvants to stimulate an immune response, particularly a mucosal immune response.

Our analysis of this patent is as follows:

Immunex Corporation’s patent US 7709618 B2 deals with BTL-II nucleic acids.
invention provides isolated BTL-II protein, nucleic acid, antibody, enemies, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods of using the compositions of the invention given. For example, the composition of the invention can be used for diagnosis and treatment of inflammatory intestinal diseases and for the development of a mucosal immune response to an antigen.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Glaxo Group Limited patent solves the following problem:

US Pat. Nos. 3,979,399, 3,840,546, and 3,966,746 (ER Squibb & sons) disclose 4-amino derivatives of pyrazolo [3,4-b] pyridine-5-carboxamides wherein the 4-amino group NR3R4 can be an acyclic amino group where P3 and R4 may each be hydrogen, lower alkyl (eg butyl), phenyl, and others.; NR3R4 otherwise be a 3-6-membered heterocyclic group such as pyrrolidino, piperidino and piperazino. The compounds disclosed as central nervous system depressant useful as ataractic, analgesic and hypotensive agents.

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 7709497 B2 deals with Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor.
invention provides 4 – {[1- (aminocarbonyl) -4-piperidinyl] amino} -N – [(3,4-dimethylphenyl) methyl] -1-ethyl-1H-pyrazolo [3,4-b] pyridine-5 – formamide, which is a compound of formula (I): or a salt thereof.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.